• Biol. Blood Marrow Transplant. · Mar 2019

    Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

    • Ankit J Kansagra, Noelle V Frey, Merav Bar, Theodore W Laetsch, Paul A Carpenter, Bipin N Savani, Helen E Heslop, Catherine M Bollard, Krishna V Komanduri, Dennis A Gastineau, Christian Chabannon, Miguel A Perales, Michael Hudecek, Mahmoud Aljurf, Leslie Andritsos, John A Barrett, Veronika Bachanova, Chiara Bonini, Armin Ghobadi, Saar I Gill, Joshua Hill, Saad Kenderian, Partow Kebriaei, Arnon Nagler, David Maloney, Hien D Liu, Nirali N Shah, Mohamed A Kharfan-Dabaja, Elizabeth J Shpall, Ghulam J Mufti, Laura Johnston, Elad Jacoby, Ali Bazarbachi, John F DiPersio, Steven Z Pavletic, David L Porter, Stephan A Grupp, Michel Sadelain, Mark R Litzow, Mohamad Mohty, and Shahrukh K Hashmi.
    • Department of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.
    • Biol. Blood Marrow Transplant. 2019 Mar 1; 25 (3): e76-e85.

    AbstractOn August 30, 2017 the US Food and Drug Administration approved tisagenlecleucel (Kymriah; Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present, ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring, and disease assessments. To address these issues experts representing the American Society for Blood and Marrow Transplant, the European Society for Blood and Marrow Transplantation, the International Society of Cell and Gene Therapy, and the Foundation for the Accreditation of Cellular Therapy formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.Copyright © 2018 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

      Pubmed     Free full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…